Breakthrough for endometriosis sufferers as first-of-its-kind pill to be available on NHS in England. This marks a significant advancement in the treatment of a condition that impacts an estimated 1.5 million women in the UK. The new drug, relugolix-estradiol-norethisterone (relugolix combination therapy or Ryeqo), offers a more comfortable and less stressful option compared to current treatments. But it will be accessible to only those patients who have already tried every alternative.

Endometriosis is a long-term condition in which tissue that's like the womb lining grows somewhere else in the body, often in the pelvis, bladder, and bowel. This ectopic tissue, like normal endometrial tissue, thickens, breaks down, and bleeds during each menstrual cycle, but without a means of exit from the body. This activity causes intense inflammation, scarring, and the development of adhesions that can lead to intense pain and fertility issues.

The condition is also legendary for its late diagnosis, with the majority of women taking nine years on average to receive an official diagnosis. Symptoms tend to be wrongly diagnosed as other conditions such as fibroids, pelvic inflammatory disease, or irritable bowel syndrome (IBS), so early detection is not always easy.

Symptoms of endometriosis are likely to include:

• Severe period pain that interferes with daily life
• Heavy menstrual bleeding
• Painful urination or bowel movements
• Lower abdominal pain in a chronic form
• Painful sex
• Fatigue and breathlessness
• Mood swings, anxiety, and depression
• Trouble conceiving

How the New Pill Works?

In contrast to existing injectable therapies that necessitate regular clinic visits, the newly approved pill provides a more convenient option for treating endometriosis at home. Relugolix combination therapy functions by inhibiting certain hormones that drive endometriosis growth while also offering required hormone replacement to offset side effects.

Conventional injectable medications have the potential to aggravate symptoms initially before they bring relief, and thus complicate the treatment process for patients. Ryeqo works faster and reduces the use of multiple drugs, which streamlines the treatment process. Patients no longer need to visit hospitals and clinics repeatedly as they can take a pill daily. Physical as well as psychological stress is also minimized.

Who Can Benefit from the New Treatment?

Although promising, the new pill will only be offered to women who have already attempted and failed other medical or surgical interventions for endometriosis. It is predicted that about 1,000 women per year will receive this treatment on the NHS.

Aside from addressing endometriosis, Ryeqo has also been approved by NICE for treating moderate to severe symptoms of uterine fibroids, another condition that affects numerous women.

Helen Knight, NICE director of medicines evaluation, underlined the significance of this approval, saying, "This new treatment represents a potential step-change in the management of endometriosis, returning control to patients while maintaining value for the taxpayer."

The release of this pill is a welcome relief, as women with endometriosis often have limited treatment options available to them. Today, managing the condition typically consists of pain killers, hormonal therapies, and, in extreme cases, operations like laparoscopies or hysterectomies.

NHS national clinical director for women's health Dr. Sue Mann emphasized the pill's benefits, saying, "This first-of-a-kind treatment for endometriosis – a condition which can be hugely debilitating – will give women more control over their own health by potentially enabling them to receive the treatment they require in the privacy of their own homes, without the necessity of going to regular appointments."

Cost and Availability of the Pill

The treatment is priced at £72 for a 28-day supply (VAT excluded). Although the cost appears high, the long-term advantages of minimizing hospital consultations and enhancing patients' quality of life make it an economical intervention in the wider healthcare context.

The pill will be accessible via standard NHS commissioning, thereby allowing those who qualify to use it without incurring extra financial costs.

What This Means for Women's Health?

The approval of Ryeqo is a welcome step in the right direction, but it also points to the continuing issues in endometriosis treatment. There are still many women who experience long delays in diagnosis and treatment, and there is an urgent need for more research, awareness, and funding for improved solutions.

Although this new pill will not cure endometriosis, it is a step in the right direction for making the disease more manageable and enhancing the quality of life for thousands of women. As medicine develops further, the desire would be for treatments to be more inclusive and accessible, eventually leading to improved outcomes for those suffering from endometriosis.

For women suffering from endometriosis, the approval of this new daily pill is a ray of hope. Reducing the necessity for the need of invasive procedures and numerous doctor visits, it enables patients to get in control of their well-being in a more convenient manner. Nevertheless, ongoing advocacy and studies have to be present to ensure that all women who suffer from the same condition get the care and treatment they need.

In many new things, there has been a groundbreaking new tool developed by the scientists of Ankara University (AU) in Turkey. This tool promises to detect lung cancer in its early stages. The best part? The tool uses nothing more than just your voice. This AI-powered application is used to analyze speech patterns in order to identify structural changes caused by the diseases. This is a great way of testing, as it is non-invasive in nature, thus is a low-cost method of screening for such a deadly disease.

Detecting Through Speech

The project is being led by Associate Professor Dr Haydar Ankishan of AU's Stem Cell Institute. The idea centered to the research was: changes in a person's voice could reflect anatomical or functional disruption in the lungs, especially those caused by cancer.

“In our study, we considered the structure of the voice, the anatomical structure of the lungs, and the circulatory system,” Ankışhan said at a press conference held at AU’s Ibn-i Sina Hospital. “We proposed that the voice could provide information about lung cancer.”

The study took a span of 18 months, with the team being able to develop a system that can detect stage-one lung cancer with an accuracy rate exceeding 90%.

How Does This Work?

The technology is able to capture a person's voice in a natural environment. Then the voice is processed using advanced signal analysis techniques and machine learning. The AI model is trained on these audio samples to differentiate between healthy individuals and those with early-stage lung cancer.

Faculty member of AU's Faculty of Medicine, who is also a key contributor in the study, Dr Bülent Mustafa Yenigün emphasized the importance of such early detection. “The later lung cancer is diagnosed, the harder it becomes to treat. We aimed for a method that’s non-invasive, low-cost, and doesn’t expose patients to harmful radiation,” he explained.

If one has to understand the science behind it, then one must understand what the AI listens for. The science behind this method is actually rooted in how tumors affect airflow and resonance in the lungs. As masses form, they can disrupt the natural vibrations and frequencies that are part of normal speech. Thus, the AI is trained to detect these variations, regardless of how subtle they may be. Many of these variations, in fact, may not be noticeable to the human ear.

“Our application identifies deviations in frequency and sound resonance that can indicate a pathological mass in the lungs,” Yenigün explained.

Is It Accessible?

The researchers are optimistic about the future. If legal approvals are secured and larger datasets are collected, they estimate that the technology could be integrated into standard lung cancer screening programs within two to three years. In a best-case scenario, it could be available in as little as one to two years.

If successful, this voice-based screening tool could become a revolutionary step in early cancer detection—accessible, painless, and potentially life-saving.

What Is Lung Cancer?

As per the NHS UK, Lung Cancer is one of the most common and serious types of cancer, which has affected more than 43,000 people in UK, annually.

In many cases there are no symptoms, however, you must look out for these:

• a persistent cough
• coughing up blood
• persistent breathlessness
• unexplained tiredness and weight loss
• an ache or pain when breathing or coughing

When cancer begins in the lungs, it is referred to as primary lung cancer. In contrast, if cancer originates elsewhere in the body and spreads to the lungs, it is known as secondary lung cancer. This explanation focuses specifically on primary lung cancer.

Primary lung cancer is broadly categorized based on the type of cells where the cancer develops. The two main types are:

Non-small-cell lung cancer (NSCLC): This is the most common form, making up about 80–85% of all cases. NSCLC includes three subtypes:

• Squamous cell carcinoma
• Adenocarcinoma
• Large-cell carcinoma

Small-cell lung cancer (SCLC): Less common than NSCLC, this type tends to grow and spread more quickly.

Understanding the type of lung cancer is essential for determining the appropriate treatment approach.

A new study titled The Global Flourishing Study, conducted by researchers from Baylor and Harvard universities have thrown light on the meaning of "flourishing" and how it does not mean being happy. The study has looked at how some countries are doing significantly better in terms of the broader sense of well-being than other countries. The study is based on responses from over 207,000 participants across 22 countries and Hong Kong. The study also assessed six core aspects of flourishing, which includes happiness, health, meaning, character, relationships, and financial stability.

What Does Being "Flourished" Really Mean?

While there are traditional happiness indexes that measures an individual's or a group's subjective well-being or happiness, the study about being "flourished" includes not just how happy people feel, but also their health. The study looks at whether people are leading a healthy life, whether they are mentally well and feel like they do have a purpose in life. The study also takes in account for strong relationships, acting with character and feeling financially secure.

The participants of this study were asked to respond to 12 key questions. They were aimed at measuring these components. The questions varied from "How satisfied are you with life?" to "Do you worry about meeting monthly expenses?"

Dr. Byron Johnson of Baylor University, who led the study, said the scale of the research is what makes it especially unique. “We are following 207,000 participants around the world in over 40 languages. This gives a voice to approximately 64% of the world’s population,” he explained.

Indonesia Leads, But Traditionally 'Happy' Nations Lag

The results too have been unexpected, unlike what we seen in the happiness indexes. Countries which were often seen as happy in global rankings did not perform as well when it came to flourishing. Indonesia, however, topped the list, followed by Mexico and the Philippines. However, nations like Sweden and the United States, which are usually high ranking in the World Happiness Report, were found to be average in terms of flourishing.

Interestingly, some of the most flourishing countries, such as Nigeria and Indonesia, did not make it to the top 20 in the World Happiness Report, indicating a crucial distinction between simple happiness and a deeper sense of well-being.

Youth Is Struggling

One of the most concerning findings of the study was that flourishing tends to increase with age. According to Dr. Tyler VanderWeele of the Harvard T.H. Chan School of Public Health, young people across most countries reported the lowest levels of flourishing, often citing a lack of purpose.

"In most countries, the youngest individuals are the ones struggling the most,” VanderWeele noted. However, there were exceptions—Tanzania and Poland showed relatively better flourishing scores among their younger populations.

The researchers suggest that in more developed countries, increased competition, job stress, and social comparison may be contributing to this generational dip. “Young people are telling us something is wrong,” added Felix Cheung, a co-author of a separate study in the World Happiness Report.

Rich, Not Flourishing

While wealthier countries usually scored higher in the financial security section, they lacked in the sections where they were asked questions on meaning and relationships.

This gap has raised questions about modern development. “How can we carry out economic growth without compromising meaning and relationships?” VanderWeele asked.

In contrast, countries with fewer economic resources but stronger community bonds and clearer cultural or spiritual values often performed better on overall flourishing metrics.

According to researchers, people can take active steps to improve their own flourishing. VanderWeele shared how one participant, after reflecting on the study’s 12 questions, decided to volunteer to find greater purpose. “Flourishing can be guided by reflection,” he said.

Still, systemic issues like conflict, inequality, and poor governance remain significant barriers. As Cheung summed it up: “When one person is unhappy, that’s an individual issue. But when a population isn’t happy, that’s a structural problem—and it requires structural solutions.”

A new ketamine-like nasal spray will soon be available at a subsidised cost in Australia to help thousands living with treatment-resistant depression. The medication, called Spravato (esketamine), has been added to the Pharmaceutical Benefits Scheme (PBS), marking a significant shift in how the country approaches difficult-to-treat mental health conditions.

What Is Esketamine and How Does It Work?

Esketamine is chemically related to ketamine, a well-known anaesthetic that gained notoriety for recreational use in rave culture. However, in controlled medical settings, this compound is offering new hope for patients who have not responded to traditional antidepressants.

Unlike older medications that target serotonin – a “feel-good” chemical in the brain – esketamine works on a different neurotransmitter called glutamate. This chemical is believed to play a key role in restoring neural connections that influence mood regulation. The result is often a much faster response, with some patients feeling relief within hours instead of weeks or months.

Why It Matters: A Breakthrough After Decades

Esketamine is the first government-funded drug for major depression in over 30 years that works via a new mechanism. While most antidepressants developed since the 1980s have focused on serotonin or other monoamines, esketamine offers an alternative path by targeting glutamate and related brain circuits.

For those who have tried multiple medications without success, this drug represents a long-awaited option. Clinical trials in Australia show that nearly 50% of patients with treatment-resistant depression reported significant improvement after using esketamine.

Who Can Access It and What Will It Cost?

Starting Thursday, up to 30,000 Australians will be able to access Spravato through the PBS. Patients will pay $31.60 per dose, or $7.70 for pensioners and concession card holders. However, this does not include additional healthcare and administrative fees. Because of safety requirements, the drug must be administered under supervision at certified treatment centres, which will add to the overall cost.

Despite these extra expenses, making esketamine available through PBS is expected to reduce financial barriers and give more Australians access to potentially life-changing care.

Why Esketamine Stands Out

Since receiving approval from the US Food and Drug Administration (FDA) in 2019, esketamine has been used in hospitals and clinics across America, particularly in emergency care for severe depression. Unlike some drugs that sedate or numb emotions, esketamine is reported to alleviate core depressive symptoms — including intense feelings of hopelessness and suicidal thoughts — without dulling awareness.

Mental health experts say this rapid effect can be life-saving in critical cases where waiting for standard medications to take effect is not an option.

A Step Forward After Long Delays

The inclusion of Spravato in the PBS comes after a four-year wait and four separate funding submissions. The listing is seen as a major win for mental health advocates and patients who have pushed for broader access to advanced treatments.

While it may not work for everyone, esketamine opens a new chapter in treating depression — one focused on faster, more targeted relief for those who need it most.